Welcome to our dedicated page for Axogen news (Ticker: AXGN), a resource for investors and traders seeking the latest updates and insights on Axogen stock.
Axogen Inc. (AXGN) delivers innovative solutions for peripheral nerve repair through clinically validated medical technologies. This dedicated news hub provides investors and healthcare professionals with essential updates on the company developments shaping surgical nerve regeneration.
Access real-time announcements including quarterly earnings reports, regulatory milestones, product launch details, and strategic partnerships. Our curated collection features press releases about Avance Nerve Graft advancements, Axoguard product line expansions, and clinical study outcomes that demonstrate Axogen's leadership in nerve repair innovation.
Bookmark this page for centralized access to financial performance data, research breakthroughs, and market expansion initiatives. Stay informed about Axogen's contributions to improving surgical outcomes through cutting-edge ECM technologies and nerve regeneration solutions.
Axogen, a leader in surgical solutions for peripheral nerve injuries, announced its participation in the Leerink Partners Healthcare Crossroads Conference.
CEO Karen Zaderej will engage in a fireside chat on May 29, 2024, at 3:40 p.m. CT / 4:40 p.m. ET in Austin, TX.
The event will be webcast live and later archived for 90 days on the company's Investors page.
Axogen, Inc. reported a 12.9% increase in revenue in the first quarter of 2024, reaching $41.4 million. The company's gross margin improved to 78.8%, while net loss decreased to $6.6 million. Adjusted net loss was $2.7 million, with adjusted EBITDA at $1.0 million. Cash, cash equivalents, and investments totaled $23.6 million. Axogen is focusing on reaching profitability, with upcoming product launches and submission milestones.
Axogen, Inc. (NASDAQ: AXGN) announces the first surgical implants of its Avive+ Soft Tissue Matrix™, a resorbable barrier for nerve injuries. The product aims to enhance nerve protection during healing phases. Surgeon feedback is positive, with a national launch expected in Q2 2024. Avive+ is a placenta-based allograft processed under FDA regulations to address various nerve injuries and defects, offering promising solutions for patients experiencing nerve trauma.
FAQ
What is the current stock price of Axogen (AXGN)?
What is the market cap of Axogen (AXGN)?
